Allergen immunotherapy for asthma.
BACKGROUND
Allergen specific immunotherapy has long been a controversial treatment for asthma. Although beneficial effects upon clinically relevant outcomes have been demonstrated in randomised controlled trials, there remains a risk of severe and sometimes fatal anaphylaxis. The recommendations of professional bodies have ranged from cautious acceptance to outright dismissal. With increasing interest in new allergen preparations and new methods of delivery, it was time to conduct another systematic review of allergen specific immunotherapy for asthma.


OBJECTIVE
The objective of this review was to assess the effects of allergen specific immunotherapy for asthma.


METHODS
We searched the Cochrane Airways Group trials register up to June 2001, MEDLINE, Dissertation Abstracts, Current Contents and reference lists of articles.


METHODS
Randomised controlled trials using various forms of allergen specific immunotherapy to treat asthma and reporting at least one clinical outcome.


METHODS
Three reviewers independently assessed eligibility of studies for inclusion. Two reviewers independently performed quality assessment of studies.


RESULTS
Seventy-five trials were included (52 of 54 previously included trials and 23 new trials). A total of 3,506 participants (3,188 with asthma) were involved. There were 36 trials of immunotherapy for house mite allergy; 20 pollen allergy trials; ten animal dander allergy trials; two Cladosporium mould allergy, one latex and six trials looking at multiple allergens. Concealment of allocation was assessed as clearly adequate in only 15 of these trials. Significant heterogeneity was present in a number of comparisons. Overall, there was a significant reduction in asthma symptoms and medication and improvement in bronchial hyper-reactivity following immunotherapy. There was a significant improvement in asthma symptom scores (standardised mean difference -0.72, 95% confidence interval -0.99 to -0.33) and it would have been necessary to treat 4 (95%CI 3 to 5) patients with immunotherapy to avoid one deterioration in asthma symptoms. Overall it would have been necessary to treat 5 (95%CI 4 to 6) patients with immunotherapy to avoid one requiring increased medication. Allergen immunotherapy significantly reduced allergen specific bronchial hyper-reactivity, with some reduction in non-specific bronchial hyper-reactivity as well. There was no consistent effect on lung function.


CONCLUSIONS
Immunotherapy reduces asthma symptoms and use of asthma medications and improves bronchial hyper-reactivity. One trial found that the size of the benefit is possibly comparable to inhaled steroids. The possibility of adverse effects (such as anaphylaxis) must be considered.
Abramson
M J
MJ
Epidemiology & Preventive Medicine, Monash University, Central & Eastern Clinical School, The Alfred, Melbourne, Vic, Australia, 3004.
Puy
R M
RM
Weiner
J M
JM
D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D003888:Desensitization, Immunologic; D006801:Humans; D007279:Injections, Subcutaneous; D016032:Randomized Controlled Trials as Topic
D000485:Allergens